LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Javier Cortés, David W. Cescon, Hope S. Rugo, S-A. Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, J. M. Perez-Garcia, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zhikun Guo, Xuan Zhou, Vassiliki Karantza, W. Pan, Peter Schmid